0
0 (0%)
Pure Bioscience, Inc. [PURE]
Source:
Company Overview
Pure Bioscience, Inc is dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC.
| Country | United States |
| Headquarters | el cajon, california |
| Phone Number | 619-596-8600 |
| Industry | manufacturing |
| CEO | Robert Bartlett |
| Website | www.purebio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.4 |
| Operating Profit | $-0.7 |
| Net Income | $-0.8 |
| Net Cash | $0 |
Profit Ratios
| Gross Margin | $0.2 |
| Operating Margin | -185.4 |
| Profit as % of Revenues | -28.5% |
| Profit as % of Assets | -114.7% |
| Profit as % of Stockholder Equity | 18.7% |
Management Effectiveness
| Return on Equity | 18.7% |
| Return on Assets | -139% |
| Turnover Ratio | 56.2% |
| EBITA | $-0.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $0.6 |
| Total Liabilities | $4.8 |
| Operating Cash Flow | $0 |
| Investing Cash Flow | |
| Financing Cash Flow | $0 |
